Aptevo Therapeutics Inc. (APVO)

NASDAQ · Pharmaceuticals & Biotech · Pharmaceutical Preparations

Price
$1.89
Day
+2.16%
Market cap
$3.41M

Close 2026-09-23.

The company

OVERVIEW We are a clinical-stage, research and development biotechnology company focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. We have developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs and have two clinical candidates and six preclinical candidates currently in development. Clinical candidate mipletamig is a CD123xCD3 T cell engager currently being clinically evaluated in the RAINIER trail, part one of a Phase 1b/2 program initiated in August 2024 for the treatment of frontline acute myelogenous leukemia (AML) in combination with standard of care venetoclax + azacitidine. Clinical candidate ALG.APV-527 targets 4-1BB (co-stimulatory receptor) and 5T4 (tumor antigen). The compound is designed to reactivate antigen-primed T cells to specifically kill tumor cells and is currently being evaluated for the treatment of multiple solid tumor types, potentially including breast, cervical, non-small- cell-lung, prostate, renal, gastric, colorectal and bladder cancers. Along with our two clinical candidates, we have six preclinical candidates. All eight molecules were developed using our proprietary ADAPTIR™ and ADAPTIR-FLEX™ protein technology platforms. We wholly own both platforms. This enables us to efficiently design and create new molecules and support long-term growth.

From Item 1: OVERVIEW.

Institutional holders

Largest positions reported on Form 13F for the quarter ended 2026-06-30, by value.

Insider trades

Open-market buys and sales filed on Form 4, newest first. Grants, option exercises and tax withholding are left out.

Recent filings